Effect of fenretinide on ovarian carcinoma occurrence.

OBJECTIVE The aim of this study was to update the effect of fenretinide, a synthetic vitamin A analogue proposed for chemoprevention, on the occurrence of ovarian carcinoma. METHODS Data were obtained from a randomized clinical trial for the prevention of second breast cancer. For the present investigation, events of interest were new primary carcinomas of the ovary arising in the fenretinide or the no-treatment (control) arm. The probability of carrying a BRCA germ-line mutation was assessed in women with ovarian carcinoma according to G. Parmigiani et al. (1998, Am J Hum Genet 62, 145-58). RESULTS Fenretinide reduced ovarian carcinoma occurrence during the 5-year intervention period (0 versus 6 cases in the fenretinide and control arm, P = 0.0327). This effect was no longer evident after the 5-year intervention period (6 versus 4 cases, P = 0.7563). Therefore with median observation time of 121 months, a total of 6 carcinomas of the ovary occurred in the fenretinide group and 10 in the control group. The probability of carrying a BRCA mutation was lower for women with ovarian carcinoma in the treatment arm. CONCLUSION Fenretinide treatment was associated with a lower incidence of ovarian carcinoma during the intervention period but such a protective effect seems to disappear after treatment. Furthermore, a possible protective effect of fenretinide in BRCA-mutated women was suggested. Further studies on fenretinide for the prevention of ovarian carcinoma particularly in women with genetic susceptibility appear necessary.

[1]  K. Berlin,et al.  Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. , 2001, Journal of the National Cancer Institute.

[2]  M. Sporn,et al.  Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. , 1999, Journal of the National Cancer Institute.

[3]  A. Sabichi,et al.  Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. , 1998, Journal of the National Cancer Institute.

[4]  L. Mariani,et al.  Chemoprevention Trial of Contralateral Breast Cancer with Fenretinide. Rationale, Design, Methodology, Organization, Data Management, Statistics and Accrual , 1997, Tumori.

[5]  F. Zunino,et al.  Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression , 1996, International journal of cancer.

[6]  C. Boni,et al.  Can fenretinide protect women against ovarian cancer? , 1995, Journal of the National Cancer Institute.

[7]  F. Formelli,et al.  Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. , 1993, Cancer research.

[8]  R. Tarone,et al.  Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. , 1988, The New England journal of medicine.

[9]  R. Lotan.  Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. , 1980, Biochimica et biophysica acta.

[10]  M. Sporn,et al.  Chemoprevention of cancer with retinoids. , 1979, Federation proceedings.

[11]  M. Sporn,et al.  N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. , 1979, Cancer research.

[12]  U. Reichert,et al.  Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo , 1998, Cancer Chemotherapy and Pharmacology.

[13]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[14]  L. Mariani,et al.  Fenretinide (4‐HPR) in chemoprevention of oral leukoplakia , 1993, Journal of cellular biochemistry. Supplement.